The phase II clinical trial results of MG-K10, an innovative anti-IL-4Rα monoclonal antibody develop
Learn moreOn October 30, 2025, the marketing authorization application for the innovative drug of Class 1, Kem
Learn moreOn September 29, 2025, the innovative monoclonal antibody drug "MG-K10 Humanized Monoclonal Antibody
Learn moreRecently, our company has discovered that some lawbreakers are using email addresses highly similar
Learn moreOn July 14th, Mabgeek Biotech submitted an application for a Hong Kong IPO, with CICC serving as the
Learn moreOn March 27th, the signing ceremony for the settlement of Mabgeek Biotech in WORLO COMPUTING-CHANGSH
Learn moreChime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma The
Learn moreRecently, the innovative monoclonal antibody drug "MG-K10 Humanized Monoclonal Antibody Injection" s
Learn moreRecently, Hunan Mabgeek Biotech Co., Ltd. (hereinafter referred to as "Mabgeek Biotech"), a leading
Learn moreSwipe to see more pictures The instructor kicked off the seminar with a unique interactive game. I
Learn moreOn March 11, 2024, Mabgeek Biotech announced that it will present the top-line data of the Phase II
Learn moreOn December 13, 2023, Mabgeek Biotech has obtained the clinical approval for a drug for sinusitis. s
Learn moreThe 2023 Bio-Europe, a major European biotechnology exhibition, was grandly held in Munich, Germany
Learn moreOn September 29, 2023, Mabgeek Biotech announced that its humanized monoclonal antibody injection ta
Learn moreOn June 29, 2023, Mabgeek Biotech announced that its MG-K10 (comekibart) humanized monoclonal antibody injection for the treatment of patients with moderate to severe atopic dermatitis has achieved th
Learn moreOn June 15, 2023, the clinical trial application for the antibody drug "MG-013 Humanized Monoclonal
Learn moreShanghai Mabgeek Biotech Co., Ltd. (hereinafter referred to as "Mabgeek Biotech") is a clinical-stage innovative drug research and development company. The company announced that its independent
Learn moreOn February 28, 2023, Heze Modern Pharmaceutical Port and Mabgeek Biotech signed a strategic coopera
Learn moreOn October 25, 2022, Shanghai Mabgeek Biotech Co., Ltd. (Mabgeek, hereinafter referred to as "Mabgee
Learn moreThe second antibody drug submitted by Mabgeek Biotech, "MG-ZG122 Humanized Monoclonal Antibody Injec
Learn moreAll Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com